These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32100826)

  • 1. The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors.
    Nandakumar V; Mills JR
    Clin Chem; 2019 Feb; 65(2):357. PubMed ID: 32100826
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor mutational burden.
    Ritterhouse LL
    Cancer Cytopathol; 2019 Dec; 127(12):735-736. PubMed ID: 31433548
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies.
    EBioMedicine; 2016 Nov; 13():1-2. PubMed ID: 27916137
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
    Yarchoan M; Hopkins A; Jaffee EM
    N Engl J Med; 2017 Dec; 377(25):2500-2501. PubMed ID: 29262275
    [No Abstract]   [Full Text] [Related]  

  • 5. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
    Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
    Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.
    Colli LM; Machiela MJ; Myers TA; Jessop L; Yu K; Chanock SJ
    Cancer Res; 2016 Jul; 76(13):3767-72. PubMed ID: 27197178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.
    Qin BD; Jiao XD; Zang YS
    Med Hypotheses; 2018 Jul; 116():111-113. PubMed ID: 29857892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAMA Oncology Patient Page. The Evolution of a Cancer.
    West HJ; Jin JO
    JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
    Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K
    Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 12. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
    Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D
    Science; 2018 Oct; 362(6411):. PubMed ID: 30309915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.
    Chabanon RM; Pedrero M; Lefebvre C; Marabelle A; Soria JC; Postel-Vinay S
    Clin Cancer Res; 2016 Sep; 22(17):4309-21. PubMed ID: 27390348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
    Xiang Z; Yu Y
    Front Med; 2019 Feb; 13(1):24-31. PubMed ID: 30659409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Importance of tumour mutation burden testing].
    Wild PJ
    Pathologe; 2019 Dec; 40(Suppl 3):366-368. PubMed ID: 31807843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selected Articles from This Issue.
    Clin Cancer Res; 2020 May; 26(10):2279. PubMed ID: 32414759
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor Mutational Burden Guides Therapy in a Treatment Refractory
    Bhangoo MS; Boasberg P; Mehta P; Elvin JA; Ali SM; Wu W; Klempner SJ
    Oncologist; 2018 May; 23(5):518-523. PubMed ID: 29386312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Administration of Immune Checkpoint Inhibitor for Cancer except for Melanoma and Lung Cancer].
    Takeda T; Hattori N; Takeda T; Noda T; Takeda H
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1271-1273. PubMed ID: 27760957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A coming of age for immune checkpoint inhibitors in cancer.
    Nipp RD; Gainor JF
    Immunotherapy; 2019 Jun; 11(8):647-650. PubMed ID: 31088238
    [No Abstract]   [Full Text] [Related]  

  • 20. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
    Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
    Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.